The University of Washington in Seattle, with support from the NIH, is conducting a clinical trial investigating the effects of Theratechnologies' TH9507 on cognitive function in healthy older adults and older adults with mild cognitive impairment.

Researchers have previously studied the effects of GRF, also known as GHRH (growth hormone releasing hormone), on cognitive function in healthy older men and women, and have found that daily treatments of GHRH in this population resulted in significantly improved cognitive function when compared to placebo, particularly on tests involving problem solving, psychomotor processing speed, and working memory. The data also suggest that such treatment might partially ameliorate cognitive declines in individuals with impaired cognitive function -- such as mild cognitive impairment and Alzheimer's disease.